Clinical assessment of a combined treatment targeting subjects with acne-prone skin

Complife Italia Srl0 sites80 target enrollmentNovember 5, 2021

Overview

2022 Results article in https://dx.doi.org/10.7241/ourd.20223.1 (added 18/07/2022)

Registry

who.int

Start Date

November 5, 2021

End Date

July 19, 2019

Last Updated

3 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Good general health
•2\. Both sexes, caucasian ethnicity
•3\. Phototype I to IV
•4\. Age between 18 and 50 years old
•5\. Acne severity from 1 to 3 according to IGA, (Investigator’s Global Assessment) severity scale,
•6\. Subjects who have not been recently involved in any other similar study
•7\. Willingness to use for face care only the creams that will be consigned at the beginning of the study
•8\. Willingness to submit before and after pictures
•9\. Willingness to use during all the study period only the products to be tested
•10\. Willingness not to use similar products that could interfere with the product to be tested

•1\. Subjects who do not meet the inclusion criteria
•2\. Pregnant/breastfeeding female or who have planned pregnancy during the study period
•3\. Subjects under systemically pharmacological treatment
•4\. Subjects under locally pharmacological treatment on the skin area monitored during the test
•5\. Subjects with congenital or acquired immunodeficiency
•6\. Subjects under treatment with food supplements which could interfere with the functionality of the product under study
•7\. Subjects who show other skin alterations on the monitored area
•8\. Subjects considered as not adequate to participate in the study by the investigator
•9\. Subjects with known or suspected sensitization to one or more test formulation ingredients
•10\. Adult protected by law (under control or hospitalized in public or private institutions for